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 Abstract 
 
Phosphodiesterase-4 in the Brain:  Effects of Pharmacological Inhibition and 
Mutation of DISC1 
 
                                                                Lan Xiao 
  
The effects of treatment with PDE4 inhibitors on cAMP/pCREB signaling, 
hippocampal neurogenesis and immobility in forced-swim test and the effects of DISC1 
mutation on cAMP/pCREB signaling, PDE4 subtypes and PDE4 activity and high- 
affinity rolipram binding state were determined. Acute treatment with PDE4 inhibitors 
increased cAMP and pCREB transiently, as determined by ELISA and Western blotting, 
respectively. Repeated treatment with PDE4 inhibitors for 16 days produced 
antidepressant-like effect as evidence by decreased immobility in forced-swim test, 
increased cAMP/pCREB signaling and enhanced hippocampal neurogenesis. PDE4 
inhibitors which preferentially interact with the high-affinity rolipram binding state, such 
as rolipram and piclamilast, produced greater effects than CDP840, which preferentially 
interacts with the low-affinity rolipram binding state.  
PDE4 exerts its normal functions by interacting with a variety of binding proteins. 
The effects of mutation of one of the most important binding proteins DISC1, a risk 
factor gene for mental disorders, were determined.  In this study, DISC1 mutant mice that 
carried truncated DISC1 proteins were used. DISC1 mutation increased cAMP and 
pCREB levels, and decreased PDE4 activity in prefrontal cortex, hippocampus and 
striatum. The PDE4B1, B3 and B4 splice variants were decreased in these three brain 
regions, while the D3 and D5 variants were decreased only in the hippocampus; PDE4A1 
and A5 splice variants were not affected by the DISC1 mutation. Previous work has 
shown greater DISC1 association with the PDE4B subtype than the other subtypes.  
Radioligand binding assays showed that the high affinity rolipram binding state was 
decreased in brain regions of DISC1 mutant mice, suggesting high affinity rolipram 
binding state is functionally associated with DISC1. 
Overall, PDE4 inhibitors which preferentially interact with the high-affinity rolipram 
binding states produced greater effects on cAMP/pCREB and behavior, as well as for 
increasing hippocampal neurogenesis. In addition, DISC1 mutation decreased PDE4 
activity and upregulated cAMP/pCREB levels. These suggest DISC1 is important for the 
normal function of PDE4 and downstream cAMP signaling. Mutation of DISC1 also 
induced a decrease in PDE4B and PDE4D, but not PDE4A splice variants.  The studies 
shed light on the understanding of the function of high-affinity rolipram binding state in 
the central nervous system and may provide a new target for antidepressant drug 
discovery and development. 
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1.1 Symptoms of Depression 
Depression was first termed as melancholia, which means black bile in Greek, by 
Hippocrates (Akiskal, 2000).  To date, depression is one of the most prevalent forms of 
mental illness in the world.  Severe form of depression influences about 2%-5% of the 
U.S. population and mild form of depression affects up to 20% of the population (Nestler 
et al., 2002).  In addition, due to the high risk of suicide, depression is a very life 
threatening disease (Blazer, 2000).  Though the symptomatology of depression has been 
described, the pathophysiology of this disorder was not understood very well until the 
middle of the 19
th
 century (Nestler et al., 2002).  In 1960, depression was defined as 
major depression based on the symptomatic criteria of Diagnostic and Statistical Manual 
and this categorization has continued (DSMIV, 2000).  This criteria include: depressed 
mood; irritability; low self esteem; feelings of hopelessness, worthlessness, and guilt; 
decreased ability to concentrate or think; change of appetite or weight; change of sleep 
habits; low energy; fatigue or increased agitation; decreased interest in pleasurable 
activities; and recurrent thinking of death or suicide.  When a number of symptoms last 
for longer than 2 weeks and normal social and occupational functions are impaired, major 
depression is diagnosed (DSMIV, 2000). 
 
1.2 Neurobiology of Depression 
Current thinking is that genetic and non-genetic factors contribute to the 
development of depression.  Though no single genes have been identified to be highly 
related to depression in a conclusive manner, approximately 40-50% of the risk for 
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depression is genetic (Fava and Kendler, 2000).  Because a variety of genes contribute to 
the development of depression, identifying a single risk gene and its effects becomes very 
difficult.  In addition, non-genetic factors such as stress, emotional stimuli, or viral 
infection might also induce the development of the depression (Burmeister, 1999).  
Generally, depression is described as a stress-related disorder.  However, stress alone is 
not sufficient to induce depression and most people who experience serious stress do not 
become depressed. This indicates that interaction between genetic predisposition and 
environmental factors contribute to the pathogenesis of depression (Nestler et al., 2002). 
To date, the neurobiology of depression could be explained by several mechanisms: 
dysfunction of the hippocampus and hypothalamic-pituitary-adrenal axis; impairment of 
neurotrophic mechanisms; and impairment of brain reward pathways. In the theory of 
regulation of the hypothalamus-pituitary-adrenal axis, parvocellular neurons that contain 
corticotrophin-releasing factor (CRF) of the paraventricular nucleus of the hypothalamus 
integrate input induced by stress.  These inputs include excitatory afferents from the 
amygdala, inhibitory afferents from the hippocampus, and inputs from the ascending 
monoamine pathways.  CRF is released from neurons located in the hypophyseal portal 
system and exerts its effects on the anterior pituitary to facilitate the release of ACTH.  
ACTH increases glucocorticoid levels, while simultaneously, inhibiting the synthesis of 
CRF and ACTH.  However, a high level of glucocorticoids damages hippocampal 
function, initiating a hypercortisolemic state associated with depression (Nestler et al., 
2002).  Despite the dysfunction of the hypothalamus-pituitary-adrenal axis having been 
associated with depression, it is still unknown whether it is the cause for depression or 
secondary to depression (Nestler et al., 2002). 
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Another hypothesis based on the pathologic effects of stress on the hippocampus 
involves the role of the neurotrophic factor in the etiology of depression.  Neurotrophic 
factors are found to regulate neural growth and differentiation during development, as 
well as plasticity and survival of adult neurons and glial cells (Duman et al., 1997; Altar, 
1999).  The neurotrophic hypothesis states that a deficiency of neurotrophic factors 
contributes to hippocampal pathology during the development of depression (Nestler et 
al., 2002).  Chronic stress decreases BDNF expression in the dentate gyrus and the 
pyramidal cell layers of the hippocampus (Smith et al., 1995).  This decrease may result 
partly from a reduction in glucocorticoids (Smith et al., 1995) and a change in 
serotonergic transmission (Vaidya et al., 1997).  In addition, chronic antidepressant 
treatment enhances BDNF expression (Nibuya et al., 1995).  Compelling studies reveal 
that severe stress induces changes in glutamatergic and monoaminergic neurons; these 
changes include the reduction of dendritic arborizations and BDNF expression. The 
reduction of BDNF is due to excessive glucocorticoid-induced reduction of transcription 
via CREB, which controls BDNF expression (Kuroda and McEwen, 1998).  
Antidepressant treatments produce the opposite effects, i.e., increased dendritic 
arborization and BDNF expression in the hippocampus via activation of CREB (Conti et 
al., 2002).  In vivo and in vitro, expression of BDNF is increased by CREB (Tao et al., 
1998; Conti et al., 2002).  Injection of CREB into hippocampal dentate gyrus increases 
CREB activity, and exerts an antidepressant-like effect in forced swim and learned 
helplessness tests (Chen et al., 2001). 
Most preclinical studies have focused on the hippocampus because of its role in the 
memory and spatial learning.  Recently, brain imaging and autopsy studies indicate 
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abnormalities in several other brain regions in patients with depression such as nucleus 
accumbens, hypothalamus and amygdala (Nestler et al., 2002).  Such regions are 
involved in the brain reward pathway.  The nucleus accumbens is part of the mesolimbic 
dopamine system, which contains dopaminergic neurons. Dopaminergic neurons in  the 
nucleus accumbens play an important role in reward (Nestler et al., 2002).  Drugs of 
abuse exert their rewarding effects via enhancing dopaminergic transmissions (Wise, 
1996; Koob et al., 1998).  Other drugs such as opiates not only activate dopaminergic 
neurons, but also  opioid receptors in the nucleus accumbens (Nestler et al., 2002).  The 
possible involvement of the nucleus accumbens in the development of depression has 
been studied for decades.  Behavioral studies demonstrate drugs of abuse decrease the 
stimulation threshold for intracranial self-stimulation (Hall et al., 1977; Wise, 1996).  The 
reinforcing effects of drugs of abuse depend in part on their ability to activate CREB in 
the nucleus accumbens (Berke and Hyman, 2000; Nestler, 2001; Shaw-Lutchman et al., 
2002).  An increase of CREB in the region decreases the sensitivity to a variety of 
aversive stimulants, while a decrease of CREB increases that sensitivity (Carlezon et al., 
1998).  Acute and chronic stress could increase the CREB-mediated transcription in the 
nucleus accumbens (Carlezon et al., 1998; Pliakas et al., 2001).  Thus, it would appear 
that CREB in the nucleus accumbens is involved in the behavioral responses to the 
stimulants (Nestler et al., 2002).  Several studies point out that dynorphin is a target gene 
downstream of the CREB signaling cascade, which may affect sensitivity to aversive 
stimuli and contribute to some symptoms of depression (Carlezon et al., 1998; Pliakas et 
al., 2001).   In addition, BDNF in the nucleus accumbens significantly enhances drug-
reward signaling (Horger et al., 1999). 
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Besides the nucleus accumbens, the hypothalamus is also regarded as contributing to 
the pathogenesis of depression.  Orexin, which is expressed in the lateral hypothalamus, 
regulates both sleep and eating activity (Willie et al., 2001).  Melanin, which is expressed 
in the lateral hypothalamus, modulates sexual and anxiety-like behaviors (Gonzalez et al., 
1996; Ahima and Osei, 2001; Monzon et al., 2001).  Melanocortin, which is expressed in 
the medial hypothalamus, regulates the anxiety-like behavior (Nestler et al., 2002).  
Furthermore, the amygdala is also involved in the molecular mechanism of depression 
due to its role in conditioned fear (Davis, 1998; Cahill et al., 1999), drug abuse, and 
natural rewards (Everitt et al., 1999; Koob, 1999; Hall et al., 2001; Josselyn et al., 2001; 
Jentsch et al., 2002).  
 
1.3 Animal Models of Depression 
Animal models have been important in studying neural factors involved in 
depression as well as the mechanism of action of antidepressant drugs.  However, there is 
no single animal model that fully captures the various aspects of depression in humans.  
The cardinal symptoms of depression such as feelings of worthless and suicidal ideation 
exhibited in humans are difficult or impossible to model in animals (Nestler et al., 2002).  
Thus, the measurements of depression-related behavior in laboratory animals depend 
primarily on two criteria, i.e., responses to antidepressants and responses to stress 
(Willner, 1995; Hitzemann, 2000; Porsolt, 2000; Lucki, 2001).  Though there are many 
limitations with the animal models described as Table 1.1, overall they are useful for 
studying the effects of new medications and the neurobiological mechanisms underlying 
depression (Nestler et al., 2002). 
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Table 1.1.  Animal Models Use for Depression/Antidepressant Research 
Model Animals Antidepressant effects 
Forced swim Rat, Mouse Decrease the time of immobility 
(Rodgers and Dalvi, 1997; Page 
et al., 1999; Zhang et al., 2002) 
Tail suspension Mouse Decrease the time of immobility 
(Rodgers and Dalvi, 1997; Zhang 
et al., 2002) 
Learned helplessness Rat, Mouse Decrease escape latency and 
failures (Hajszan et al., 2009) 
Olfactory bulbectomy Rat, Mouse Partially reverse behavioral 
abnormalities induced by lesion 
(Breuer et al., 2009) 
Social defeat stress Rat, Mouse Increase the time spent in the 
interaction zone (Brown et al., 
2011) 
Chronic mild stress                          Rat,  Mouse Reverse changes in sucrose 
consumption, corticosterone 
level (Willner et al., 1987; Li et 
al., 2007) 
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Maternal deprivation Rat, Mouse Decrease the HPA axis 
responsiveness, anxiety 
behaviors and alcohol 
consumption (Huot et al., 2001) 
Differential reinforcement of 
low rate (DRL) 
Rats, Mouse Decrease response rate and 
increase reinforcement rate 
(O'Donnell and Seiden, 1983; 
van Hest et al., 1992) 
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1.4 Treatment of Depression 
There are several antidepressant treatments effective for patients with depression. 
Older treatments include electroconvulsive seizures, tricyclic antidepressants (TCAs), 
and monoamine oxidase inhibitors (MAOIs). The original tricyclic antidepressants, e.g., 
imipramine, arose from research on the behavioral effects of antihistamines, while 
monoamine oxidase inhibitors, e.g., iproniazid, were originally derived from drugs used 
to treat tuberculosis (Nestler et al., 2002).  Both of these classes of drugs relieve the 
symptoms of depression, but have a very poor tolerability and risk profile (Feighner, 
1999).   The finding that these drugs can relieve depression shed a light on the molecular 
mechanism that modulates depressive symptoms in the brain.  Over the past 50 years, 
depression research has been focused on understanding of how these drugs work and on 
finding better drugs with better tolerability and safety (Dubarek and Kucia, 2007).  This 
led to the development of a number of second-generation antidepressants, which includes 
selective serotonin reuptake inhibitors (SSRIs), reversible inhibitors of monoamine 
oxidase A (RIMAs; e.g.,moclobemide), selective norepinephrine reuptake inhibitors (e.g., 
reboxetine), dual norepinephrine and serotonin reuptake inhibitors (e.g., milnacipram, 
venlafaxin, duloxetine), and some other  drugs with distinct neurochemical actions 
(Nelson, 1997; Stahl, 1998).  Studies in patients and animal models provide clues to how 
brain function is altered by antidepressant treatment (Pacher and Kecskemeti, 2004).  
Unfortunately, even the more recently developed antidepressants are still of limited utility 
due to their incomplete efficacy and side effects (Blier, 2001).  Further, their mechanism 
of action remains incompletely understood.  Notably, inhibition of serotonin and 
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norepinephrine reuptake enhances the actions of transmitters immediately but 
antidepressants exert their behavioral effects only after a period of sustained treatment 
(Blier, 2001).  This suggests that adaptation to the increased neurotransmission 
contributes to antidepressant efficacy.  
 
1.5 Phosphodiesterase-4 
Cyclic nucleotide phosphodiesterase (PDE) enzymes were first discovered by 
Thompson and Appleman in a variety of tissues from different species (Thompson and 
Appleman, 1971a; Thompson and Appleman, 1971b).  To date, eleven families have been 
identified according to their substrate specificity, inhibitor sensitivities, and kinetic 
properties (Lugnier, 2006).  Based on the substrate, the PDE family is divided into three 
groups:  cAMP-specific PDEs, including PDE4, PDE7, and PDE8; cGMP-specific PDEs, 
including PDE5, PDE6, and PDE9; and dual-substrate PDEs, including PDE1, PDE2, 
PDE3, PDE10, and PDE11.  All the PDE families have the same general structure, which 
includes a highly conserved catalytic domain within the central to C-terminal region and 
variable, differentially spliced, N-terminal regions responsible for regulating enzyme 
activity and intracellular location (Beavo and Brunton, 2002; Houslay and Adams, 2003).  
Among PDE families, PDE4 is the most critical enzyme for modulating intracellular 
cAMP levels in the brain.  PDE4 was first described by Reeves using ion-exchange 
chromatography to separate fractions of PDE activity from heart tissue; the fourth peak of 
PDE activity was found to be specific for cyclic AMP (Reeves et al., 1987); at the time, it 
was termed PDE IV.  Further study revealed that PDE4 has high affinity for cAMP but 
not cGMP (Km value for cAMP is 1-3 uM) and that is potently inhibited by rolipram 
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(Bolger et al., 1996; Nemoz et al., 1997; Francis et al., 2001). To date, four subtypes of 
PDE4 have been identified; these are encoded by four genes, PDE4A, B, C, D, which 
encode 25 different splice variants.  These PDE4 splice variants are divided into three 
groups: long form; short form, and super-short form as shown in Figure 1.1 (O'Donnell 
and Zhang, 2004; Houslay et al., 2007).  Long form PDE4 contains upstream conserved 
regions UCR1 and UCR2.  UCR1 has a conserved domain which can be phosphorylated 
by cAMP-dependent protein kinase (PKA).  This modification enhances the activity for 
hydrolyzing cAMP (Sette and Conti, 1996; MacKenzie et al., 2002).  Short form PDE4 
has UCR2 but not UCR1, while the super-short form only has part of UCR2 (Johnston et 
al., 2004; Houslay et al., 2007; Chandrasekaran et al., 2008; Lynex et al., 2008). All the 
PDE4 enzymes have a highly conserved catalytic domain in the central to C-terminal 
region.  In addition, PDE4B, C, and D also contain an ERK phosphorylation site in the 
catalytic domain, which regulates long, short, and super-short forms differentially 
(Houslay et al., 2007). 
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Figure 1.1 Structure of PDE4 enzymes.   PDE4 has four genes, PDE4A, B, C and D; each 
expresses approximately 3-11 alternative spliced variants at N-terminus. According to 
their structure, PDE4 are classified as long, short and super-short forms (Zhang, 2009) 
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1.6 High and Low Affinity Rolipram Binding States  
Based on the binding of the inhibitor rolipram, PDE4 has two different 
conformations termed the high-affinity rolipram binding state (HARBS) and the low- 
affinity rolipram binding state (LARBS); rolipram exhibits Kd values of approximately 2 
nM and 200 nM, respectively, for these conformations (Jacobitz et al., 1996; Souness and 
Rao, 1997).  The HARBS is present in the brain, while the LARBS is present in both 
brain and peripheral tissues (Kaulen et al., 1989; Souness and Rao, 1997; Zhang et al., 
2006).  Consistent with their distribution, the HARBS is associated with head twitches, 
tremor, hypothermia, and emesis (Schmiechen et al., 1990), while the LARBS is 
associated with anti-inflammatory effects (Souness and Rao, 1997).   Chronic 
antidepressant treatment induces an increase in the HARBS but not the LARBS in rat 
brain (Zhao et al., 2003a).  
It has been shown that PDE4 inhibitors, rolipram preferentially binds to the HARBS 
while CDP840 has some preference for the LARBS; piclamilast binds with equal, high 
affinity to both the HARBS and the LARBS (Zhao et al., 2003a).  All three compounds 
can penetrate the blood brain barrier after peripheral administration (Zhang et al., 2006).   
Jacobitz and coworkers have shown that PDE4 inhibitors bind to both the HARBS and 
LARBS at the catalytic site; the HARBS depends on the presence of N-terminal domain 
of the protein (Jacobitz et al., 1996).   Overall, all the studies suggest HARBS and 
LARBS represent inhibitor binding to the same site but to different conformations, 
resulting in different, inhibitor-specific, binding affinities.  It is likely that interactions of 
PDE4 with other proteins in the brain may stabilize the HARBS (Zhang et al., 2006). 
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1.7 PDE and Antidepressant Effects 
The cAMP signaling pathway is involved in the therapeutic actions of 
antidepressants and the antidepressant-like effects of PDE4 inhibitors (Table 1.2) (D'Sa 
and Duman, 2002; Manji et al., 2003).  Mice deficient in the PDE4D subtype exhibit 
increased cAMP signaling in the brain and an antidepressant-like behavioral phenotype 
effect, as evidenced by decreased immobility time in the forced-swim test (Zhang et al., 
2002).   Chronic antidepressant treatment increases CREB mRNA and protein levels in 
rat hippocampus compared with non-antidepressant, psychotropic drug treatment (Nibuya 
et al., 1996).  In addition, repeated treatment with rolipram increases CREB activity and 
phosphorylation in rat cerebral cortex (Itoh et al., 2004; Monti et al., 2006).   Chronic 
antidepressant treatment also increases cAMP signaling at several levels, including up-
regulation of the stimulatory GTP-binding protein Gs to adenylyl cyclase, activation of 
PKA and enhanced expression and function of CREB (Duman and Vaidya, 1998).   
Animal studies also suggest that electroconvulsive shock, an effective antidepressant 
treatment, also potentiates cAMP signaling, including CREB (cAMP response element 
binding protein) and neurotrophic factor BDNF (Nibuya et al., 1996; Frechilla et al., 
1998).  Other studies demonstrate that over-expression of CREB in the hippocampus 
exerts antidepressant-like effects in preclinical models (Chen et al., 2001).  Further, 
chronic antidepressant treatment increases the expression of PDE4 in the frontal cortex 
and nucleus accumbens via a compensatory mechanism (Takahashi et al., 1999).   
Overall, these findings suggest that induction of CREB function via the cAMP-signaling 
cascade by PDE4 inhibitors plays a pivotal role in their antidepressant actions.   
15 
 
Neurogenesis occurs in the adult brain of different species, including humans, rats, 
mice and monkeys; it is regulated by a variety of neurochemical, endocrine, and 
environmental factors (van Praag et al., 2005).  Exercise and enriched environmental 
conditions enhance neurogenesis; aging and stress decrease it (Cameron and McKay, 
1999).  Recent studies have suggested that depression is associated with decreased 
volume and function of the hippocampus that may result from reduced neurogenesis; 
antidepressants increase hippocampal function by increasing neurogenesis via the 
cAMP/CREB signaling pathway as described in figure 1.2 (Takahashi et al., 1998; 
Nakagawa et al., 2002).  Increased neurogenesis is associated with antidepressant-like 
effects on behavior and enhanced learning and memory (Finkbeiner, 2000; Santarelli et 
al., 2003). 
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Table 1.2 PDE4 inhibitors 
 Rolipram Piclamilast CP840 
MF C16H21NO3 C18H18Cl2N2O3 C25H27NO2 
IUPAC 4-3-cyclopentyloxy-4-
methoxyphenylpyrrolidin-2-
one 
3-cyclopentyloxy-N-3,5-
dichloropyridin-4-yl-4-
methoxybenzamide 
4-[2R-2-3-cyclopentyloxy-4-
methoxyphenyl-2-
phenylethyl]pyridine 
Structure 
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Figure 1.2. Modulation of the cAMP/CREB signaling pathway by PDE4 inhibitors. PDE4 
inhibitors, e.g., rolipram, increase cAMP levels by inhibiting PDE4 activity, thus 
increasing phosphorylation of CREB which initiates transcription of a number of genes. 
P, phosphate group; CREB, cAMP response element binding protein; DISC1, disrupted 
in schizophrenia 1. 
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1.8 Genetic Linkage Studies of Disrupted in Schizophrenia 1 (DISC1) 
Major mental diseases consist of schizophrenia, schizoaffective disorder, bipolar 
disorder and major depression.  The incidences of these diseases have increased during 
the past years and are very devastating in humans (Devon et al., 2001).  These diseases 
share some common symptoms and risk factors and are induced by combination of both 
genetic and environmental effects (Semple et al., 2001).  Current studies have pointed out 
that environmental factors play an important role in neuronal development which 
contributes to the pathogenesis of mental diseases (Badner and Gershon, 2002). 
Mutations in “Disrupted in Schizophrenia 1” (DISC1) have been shown to be a risk factor 
for mental illness, including schizophrenia, bipolar disorder, and depression (Hodgkinson 
et al., 2004; Millar et al., 2004).  
DISC1 was first reported in a Scottish family.  In this family, 34 of the 77 people 
carried a translocation between chromosome (t1: 11) (q43, q21) by genetic analysis, and 
16 of 34 carriers were diagnosed with psychiatric illness compared with 5 out of 43 
members without translocation (St Clair et al., 1990).  This provides strong evidences for 
the link between DISC1 and psychiatric illness (Blackwood et al., 2001).  Studies of a 
Finnish population also show a strong linkage between schizophrenia or schizoaffective 
disorder and the disruption of DISC1 gene (Ekelund et al., 2001).  Furthermore, genetic 
analysis of populations in Taiwan, Scotland, Iceland, and Britain also suggest an 
association of DISC1 gene with psychiatric illness (Liu et al., 2006). 
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1.9 DISC1 Expression in Developing Brain and Adult Brain 
Studies indicate that DISC1 is distributed in many human tissues such as heart, brain, 
and placenta at both RNA and protein levels (Millar et al., 2000a).  Studies of the 
postmortem human brain show that DISC1 expression is expressed widely (Lipska et al., 
2006).  Studies of rodents and primates including African Green Monkeys and Rhesus 
Monkeys by western blotting and immunohistochemistry also show similar expression 
patterns of DISC1 as that observed in humans (Austin et al., 2003; Bord et al., 2006).  
DISC1 plays an important role in early brain development and adult brain function.  In 
the developing mouse brain, DISC1 is distributed throughout the brain, particularly in the 
bed nucleus of stria terminals, neocortex, limbic system, and thalamic nuclei, and 
maintained in the hippocampus throughout development (Austin et al., 2004).  By 
immunohistochemistry and western blotting, DISC1 is detected at every stage from 
embryonic day 10 to 6 months old, with two peaks of expression at E13.5 and P35 
(Schurov et al., 2004). These time points are important stages for the mouse brain 
development, especially neurogenesis in the hippocampus.  The pattern and timing of the 
expression indicates a role of DISC1 in the brain development and maturation (Miyoshi 
et al., 2003; Ozeki et al., 2003; Austin et al., 2004; Schurov et al., 2004) 
 
1.10 DISC1 Protein Interaction 
Examination of DISC1 by immunocytochemistry reveals a cytoplasmic location and 
overlap with F-actin, a-tubulin, MAP2, and gelsolin, indicating that DISC1 interacts with 
many cytoskeletal proteins (Miyoshi et al., 2003; Brandon et al., 2004; Kamiya et al., 
2005).  DISC1 localizes to the centrosome via interaction with LIS/NDEL, modulating 
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local microtubule dynamics (Morris et al., 2003).  Over-expression of C-terminal 
truncated DISC1 disrupts assembly of LIS1, NDEL, dynein, dynactin, as well as y-
tubulin and pericentrin B; this mutation of DISC1 also disrupts the organization of 
microtubules (Kamiya et al., 2005).  In addition, kinesin-1 heavy chain KIF5B and 14-3-
3  are identified by mass spectrometry as interacting with DISC1.  Further studies 
demonstrate that 14-3-3 , LIS1 and NDEL1 are necessary for the axonal growth, and this 
function only exists in the presence of DISC1 and kinesin (Taya et al., 2007).  The 14-3-3 
gene is decreased in patients with schizophrenia and upregulated in the prefrontal cortex 
of the monkey by the psychiatric treatment with haloperidol and fluoxetine, which are 
used to treat schizophrenia and depression, respectively (Middleton et al., 2005; Cecconi 
et al., 2007).  Affinity chromatography has shown that growth factor receptor-bound 
protein Grb2 also interacts with DISC1 (Shinoda et al., 2007).  Studies using RNA 
interference demonstrate that Grb modulates microtubules assembly and facilitates axon 
elongation via a DISC1-dependent process (Shinoda et al., 2007).  Fasciculation and 
Elongation Factor Zeta (FEZ1) also has been shown to interacts with DISC1 in rat brain 
(Honda et al., 2004; Ikuta et al., 2007).  Reduced expression of FEZ1 compromises axon 
growth, while over-expression of FEZ1 increases DISC1 binding and neurite length 
(Miyoshi et al., 2003).  Yeast two-hybrid studies demonstrate that DISC1 interacts with a 
number of other proteins, including activating transcription factor 4 (ATF4) (Morris et 
al., 2003; Pletnikov et al., 2007), microtubule-associated protein 1A (MAP1A) (Halpain 
and Dehmelt, 2006), TNF receptor-associated factor 3 interacting protein 1 
(TRAF3IP/MIP-T3 )  (Halpain and Dehmelt, 2006), and DISC1-Binding Zinc-finger 
protein (DBZ) (Hattori et al., 2007).  Compromised binding of these proteins impairs 
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cortical development and neurite outgrowth.  Taken together, these studies show that 
DISC1 is involved in the processes that are essential for brain development and that 
dysfunctions in its function may contribute to the pathogenesis of mental illness (Chubb 
et al., 2008). 
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Figure 1.3 Interaction between DISC1 and long form PDE4B. Long form PDE4B contain 
regulatory domain including UCR1 and UCR2, catalytic domain, and amino-terminal and 
carboxy-terminal regions. The enzyme can be activated by phosphorylation by PKA on 
UCR1 and inhibited by ERK phosphorylation of the catalytic domain. DISC1 binds to the 
UCR2 domain of PDE4B, as well as other PDE4 subtypes, and may induce 
conformational changes in DISC1 or PDE4B (Mackie et al., 2007).   
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1.11 DISC1 and Psychiatric Illness 
To date, there are only a few studies of DISC1 expression in patients with major 
mental illness.  It has been reported that there are no differences of full length of DISC1 
in the postmortem brain samples between schizophrenia and controls, and antipsychotic 
treatment does not alter its expression (Lika et al., 2006).   Two studies of DISC1 have 
been performed in the lymphoblastoid cell lines from patients with psychiatric illness.  In 
cell lines from patients with t(1:11), the expression of DISC1 mRNA and protein  are 
decreased compared with controls (Millar et al., 2005).  In cell lines from patients with 
bipolar disorder, the mRNA of DISC1 also is decreased compared with normal family 
members (Maeda et al., 2006).  In addition, the decreased expression of DISC1 mRNA is 
also correlated with the manic symptoms in bipolar patients (Maeda et al., 2006).  Further 
studies reveal that antipsychotic treatment in mice up-regulates the DISC1 expression in 
both the frontal cortex and the hippocampus (Chiba et al., 2006).  Though the data on 
DISC1 in patients with psychiatric illness are limited and controversial due to the 
differences in samples and method of preparation, extensive studies of DISC1 
demonstrate that as a hub protein, DISC1 links a variety of signaling pathways, including 
the cAMP signaling, kinesin-mediated transportation, neurite growth and elongation 
(Mackie et al., 2007).  Meanwhile, it forms complexes with considerable scaffolding 
proteins. Therefore, compromised DISC1 function could enhance the risk of developing 
mental major diseases (Roberts, 2007).   
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Chapter 2 
Effects of repeated treatment with phosphodiesterase-4 
inhibitors on cyclic AMP signaling, hippocampal neurogenesis, 
and behavior in the forced-swim test 
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Abstract 
The effect of acute and chronic treatment with the phosphodiesterase-4 (PDE4) 
inhibitors rolipram, piclamilast, and CDP840, which differ in their interactions with high- 
and low-affinity binding conformers, were determined on cyclic AMP signaling, 
hippocampal neurogenesis, and immobility in the forced-swim test in rats.  Acute 
treatment with rolipram (3 mg/kg), piclamilast (1 mg/kg), or CDP840 (30 mg/kg) induced 
transient increases in cyclic AMP and phosphorylation of cyclic AMP response element 
binding protein (pCREB) in rat hippocampus and prefrontal cortex.  Chronic treatment 
with rolipram (1, 3 mg/kg), piclamilast (0.3, 1 mg/kg), or CDP840 (10, 30 mg/kg) also 
increased cyclic AMP and pCREB in hippocampus and prefrontal cortex.  In addition, 
chronic treatment with the PDE4 inhibitors increased proliferation and survival of 
neurons in the hippocampus and, simultaneously, produced antidepressant-like effects on 
behavior, as evidenced by decreased immobility in the forced-swim test.  Compared with 
rolipram and piclamilast, CDP840 exerted lesser effects on neural and behavioral 
measures, likely due to its weak interaction with the high-affinity binding conformer of 
PDE4.  Overall, the PDE4 inhibitors rolipram, piclamilast, and CDP840 exert their 
antidepressant effects via activation of cyclic AMP/pCREB signaling cascade and 
increase in hippocampal neurogenesis; this appears to involve inhibitor interaction with 
the high-affinity binding conformer. 
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Introduction 
Phosphodiesterase-4 (PDE4) plays a critical role in modulating cyclic AMP 
signaling and is involved in many aspects of cell function (Conti et al., 2003; Houslay 
and Adams, 2003; O'Donnell and Zhang, 2004).  Altered cyclic AMP signaling has been 
suggested to contribute to the pathophysiology of neuropsychiatric illnesses such as 
major depression, schizophrenia, and dementia (Tanis and Duman, 2007).  Consistent 
with this idea, it has been found that PDE4 inhibitors such as rolipram, which increase 
cyclic AMP signaling, exert antidepressant- and antipsychotic-like effects, as well as 
memory-enhancing effects, on behavior (O'Donnell and Zhang, 2004; Blokland et al., 
2006; Siuciak, 2008). 
Antidepressant-like effects of PDE4 inhibitors have been demonstrated using a 
number of preclinical models.  Early work demonstrated an antidepressant-like 
behavioral profile for rolipram, including reversal of the effects of reserpine and 
potentiation of yohimbine toxicity (Wachtel and Loschmann, 1986; Wachtel and 
Schneider, 1986).  Rolipram and other PDE4 inhibitors also reduce response rate and 
increase reinforcement rate of rats under a differential-reinforcement-of-low-rate 
schedule of reinforcement (O'Donnell, 1993); such an effect is indicative of an 
antidepressant action (O'Donnell et al., 2005).  PDE4 inhibitors are active in preclinical 
antidepressant screens such as the forced-swim and tail-suspension tests (O'Donnell and 
Zhang, 2004).  To the extent they have been examined, the antidepressant-like behavioral 
effects of PDE4 inhibitors persist with repeated treatment (Li et al., 2009).  Finally, 
clinical studies have demonstrated antidepressant effects of rolipram; however, issues 
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related to side effects and toxicity have limited its clinical utility (Zeller et al., 1984; 
Fleischhacker et al., 1992).   
There are four PDE4 subtypes, PDE4A, B, C, and D, which undergo differential 
splicing resulting in 25 PDE4 isozymes.  Through the examination of the behavioral 
phenotypes of mice deficient in PDE4 subtypes, some understanding of their relative 
roles has begun to emerge.  Mice deficient in PDE4D exhibit an antidepressant-like 
behavioral phenotype, as evidenced by reduced immobility in the forced-swim and tail-
suspension tests, and altered hippocampal LTP and memory (Zhang et al., 2002; Rutten 
et al., 2008).  PDE4B-deficient mice exhibit an anxiogenic behavioral profile, as well as 
reduced prepulse inhibition of an acoustic startle response, consistent with an 
antipsychotic-like effect (Siuciak et al., 2007; Zhang et al., 2007).  The behavioral effects 
of rolipram, which is not subtype-selective, are somewhat diminished in both PDE4D- 
and PDE4B-deficient mice (Zhang et al., 2002).  There are no published data as yet on 
the behavioral consequences of PDE4A deficiency and PDE4C is not expressed in the 
brain.   
While rolipram does not inhibit the PDE4 subtypes with different potencies, its 
interaction with the enzyme is complex.  Using an equilibrium dissociation assay, it was 
found that [
3
H]-rolipram binds to PDE4 with two distinct affinities, which have been 
termed the high- and low-affinity rolipram binding states (HARBS, LARBS) (Jacobitz et 
al., 1996).  This has been confirmed using [
3
H]-piclamilast, a PDE4 inhibitor which binds 
with equal, high affinity to the HARBS and LARBS; interestingly, while LARBS is 
found both in the brain and peripheral tissues, the HARBS is only found in the brain 
(Zhao et al., 2003a).  Consistent with this, it has been observed that the HARBS and 
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LARBS mediate distinct pharmacological effects (Saccomano et al., 1991; Barnette et al., 
1996; Zhao et al., 2003a).   
It appears that PDE4 is involved in signaling pathways affected by antidepressant 
drugs.  Repeated treatment of mice with antidepressants or rolipram increases the 
expression of PDE4 in cerebral cortex and hippocampus, with the PDE4D subtype being 
affected the most consistently (Dlaboga et al., 2006).  There appears to be some species 
dependence since similar treatment of rats has pronounced effects on PDE4A expression 
(Takahashi et al., 1999; Ye et al., 2000).  It is likely that increased PDE4 expression is a 
compensatory change in response to increased cyclic AMP signaling that results from 
antidepressant treatment; prior work demonstrated such regulation of PDE4 in neurons 
(D'Sa et al., 2002; Hajjhussein et al., 2007).  Repeated treatment of rats with 
antidepressant drugs also increases the HARBS, but not the LARBS in cerebral cortex 
and hippocampus (Zhao et al., 2003a).  Consistent with this finding, comparison of the 
acute behavioral effects of rolipram, piclamilast, and CDP840, PDE4 inhibitors that differ 
in their interactions with the HARBS and LARBS (Zhao et al., 2003b), suggests a 
predominant role for the HARBS in mediating antidepressant-like effects on behaviors 
(Zhang et al., 2006).   
The effects of antidepressants on behavior depend to some degree on increased 
neurogenesis in the dentate gyrus of the hippocampus.  Inhibition of neurogenesis blocks 
some, but not all, effects of antidepressants on behavior (Santarelli et al., 2003; Holick et 
al., 2008).  Similarly, repeated treatment of mice with rolipram, which increases cyclic 
AMP signaling, as evidenced by an increase in phosphorylation of cyclic AMP response 
element binding protein (pCREB), also increases hippocampal neurogenesis; inhibition of 
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rolipram-induced neurogenesis reduces antidepressant-like effects on behavior (Li et al., 
2009).  The relationship among the ability of PDE4 inhibitors to interact with the 
HARBS and LARBS to alter cyclic AMP signaling, increase neurogenesis, and produce 
antidepressant-like effects on behavior has not been well characterized.  Comparison of 
the effects of rolipram, piclamilast, and CDP840 on these measures should provide some 
insight, since acutely they affect behavior differently, even though all are potent PDE4 
inhibitors (Zhang et al., 2006).  In addition, such a comparison will show the extent to 
which the HARBS and the LARBS contribute to altered cyclic AMP signaling in the 
brain and increased hippocampal neurogenesis.  The present study compared the effects 
of repeated treatment with these three PDE4 inhibitors on behavior in the forced-swim 
test, hippocampal neurogenesis measured using flow cytometry, and cyclic AMP 
signaling assessed by measurement of cyclic AMP and pCREB following euthanasia by 
focused microwave fixation to prevent post-mortem changes.  The results suggest the 
importance of the HARBS in these measures and a close association among increased 
cyclic AMP signaling, neurogenesis, and antidepressant-like effects on behavior.  
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Materials and Methods 
Animals  
Male Sprague-Dawley rats (Harlan, Indianapolis, IN), weighing 200-250 g, were 
housed individually in clear plastic cages in a room that was maintained at 22C with a 
12-h on/12-h off light cycle lights on at 7:00 a.m. Food and water were freely available.  
All experiments were carried out according to the “NIH Guide for the Care and Use of 
Laboratory Animals,” revised 1996, and were approved by the Institutional Animal Care 
and Use Committee of West Virginia University.  
 
Drug Treatments 
Rolipram was purchased from Sigma Aldrich (ST. Louis. MO); piclamilast and 
CDP840 were provided by Memory Pharmaceuticals (Montvale, NJ).  To assess the 
effects of repeated treatment, rats were injected i.p. with 1 or 3 mg/kg rolipram, 0.3 or 1 
mg/kg piclamilast, 10 or 30 mg/kg CDP840, or the 10% DMSO/saline vehicle once daily 
for 16 consecutive days.  Two hours after the last treatment, separate groups of rats were 
subjected to the five-minute forced-swim test, used for measurement of cyclic AMP and 
pCREB, or started on the BrdU treatment regimen for assessment of neurogenesis.   
      To assess the effects of acute treatment on forced-swim behavior, 0.3, 1, or 3 mg/kg 
rolipram, 0.3, 1 or 3 mg/kg piclamilast, 3, 10 or 30 mg/kg CDP840, or vehicle was 
administered to separate groups of rats and the time of immobility assessed either 0.5 or 2 
hrs post-treatment.  To assess the effects of acute treatment on the neurochemical 
measures, 3 mg/kg rolipram, 1 mg/kg piclamilast, 30 mg/kg CDP840, or vehicle was 
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administered and rats were killed by focused microwave fixation 0.5, 1, 2, 3, or 4 hrs 
later.   
 
Measurement of Cyclic AMP and pCREB 
To prevent post-mortem changes in cyclic AMP and pCREB, rats were killed by 
focused microwave fixation (O'Callaghan and Sriram, 2004) (Muromachi Microwave 
Applicator, TMW-4012C, 10kW output; Stoelting, Kiel, WI).  For cyclic AMP 
measurement, hippocampus and prefrontal cortex were homogenized in ice-cold 0.1N 
hydrochloric acid and centrifuged at 13,000 g for 50 min at 4ºC.  Cyclic AMP in the 
supernatant was measured by ELISA (Assay Designs, Ann Arbor, MI) and normalized to 
protein content(Smith et al., 1985) (Bio-Rad Laboratories, Hercules, CA).   
For CREB and pCREB measurement, hippocampus and prefrontal cortex were 
homogenized in ice-cold RIPA lysis buffer (Upstate, Temecula, CA) and centrifuged at  
10,000 g for 30 min at 4C.  Solubilized samples were mixed with equal volumes of 
Laemmli sample buffer and heated to 100C for 2 minutes.  Equal amounts of sample 
protein were loaded onto gels for SDS-PAGE.  Following separation by electrophoresis, 
proteins in the gels were transferred to nitrocellulose membranes, which were incubated 
overnight at 4C with primary antibodies against CREB or pCREB (i.e., phosphorylated 
at serine-133, Millipore Billerica, MA) and then with Alexa Fluor 680-conjugated 
secondary antibody for 30 min at room temperature (Invitrogen, Carlsbad, CA).  An 
Odyssey Infrared Imaging System (LI-COR Bioscience, Lincoln, NE) was used for 
quantifying fluorescence.  Treatment-induced changes in CREB and pCREB were 
assessed within individual gels/immunoblots by densitometry.   
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Measurement of Neurogenesis by Flow Cytometry 
To evaluate the effects of repeated treatment with PDE4 inhibitors on hippocampal 
cell proliferation, rats were administered 100 mg/kg BrdU, i.p.,two hours after the last 
injection of PDE4 inhibitors in order to label dividing cells; rats were killed and BrdU 
labeling quantified 24 hours later.  To evaluate effects on hippocampal cell survival, rats 
were administered 100 mg/kg BrdU, i.p., 4 times at 2 hours intervals one day after the 
last injection of the PDE4 inhibitors; rats were killed and BrdU labeling quantified five 
weeks later. 
Neurogenesis in the hippocampus was measured by flow cytometry as described 
previously (Bilsland et al., 2006; Balu et al., 2009).  Rats were killed by decapitation and 
hippocampi were dissected, placed in 1.5ml Eppendorf tubes containing Dulbecco's 
phosphate-buffered saline (D-PBS; Invitrogen, Carlsbad, CA) and finely minced.  An 
enzymatic cocktail comprised of digestive solution (papain 2.5 U/ml, dispase 1 U/ml, and 
DNase I 250 U/ml) was added to each tube, which was then incubated at 37C for 30 
min.  The samples were triturated and washed twice with DMEM/10% fetal bovine serum 
and then once with D-PBS.  
The samples were centrifuged at 500 x g for 5 min and stained using a FITC BrdU 
Flow Kit (BD Bioscience, San Jose, CA).  Precipitated cells were suspended in BD 
Cytofix/Cytoperm buffer and incubated for 30 min on ice.  After washing twice with 1 ml 
of BD perm wash buffer, the cells were further permeabilized by resuspension with 
Cytoperm Plus buffer on ice for 10 min.  After washing, the cells were refixed in Cytofix-
Cytoperm buffer for 5 min and then incubated with DNase for 1 hr at 37C.  After 
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washing with BD buffer, the cells were labeled with 50µl of FITC-conjugated anti-
BrdU1:50 for 20 min.  After another wash, cells were labeled with 20µl of 7-AAD at 
room temperature.  The BrdU-positive cells were counted by FACS Calibur and analyzed 
using Cellquest Prosoftware (Becton Dickinson, BD Bioscience, San Jose, CA). 
 
Forced-Swim Test 
The forced-swim test was performed as described previously (Zhang et al., 2006); 
this consisted of a 15-min pre-test and a 5-min test 24 hr later.  Rats were place 
individually in a Plexiglas cylinder 45 cm high ×  20 cm diameter filled with water 22-
23°C to a depth of 30 cm.  During the 5-min test, the time of immobility, defined as 
floating in an upright position with the only movement being that necessary for an animal 
to keep its head above water, was recorded.  
 
Data Analysis and Statistics 
Data were analyzed by one-way analysis of variance followed by Dunnett’s test.  
Data are expressed as means  SEM.  A p value of < 0.05 was considered statistically 
significant. 
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Results 
Effects of repeated treatment with rolipram, piclamilast, and CDP840 on cyclic 
AMP and pCREB. 
Repeated treatment for 16 days with the PDE4 inhibitors increased cyclic AMP in 
hippocampus and prefrontal cortex (Fig.2.1).  Significant increases were observed only at 
the higher doses of rolipram (3 mg/kg), piclamilast (1 mg/kg), or CDP840 (30 mg/kg) 
that were tested. At the higher doses, rolipram, piclamilast, and CDP840 increased cAMP 
by 204%, 250%, and 145%, respectively, in hippocampus and by 168%, 189%, and 
112%, respectively, in prefrontal cortex.   
Parallel effects of repeated treatment with the PDE4 inhibitors on pCREB were 
observed (Fig.2.2).  However, both the lower and higher doses tested were effective:  
doses of 1, 3 mg/kg rolipram increased pCREB in hippocampus by 59% and 75%, 
respectively;0.3, 1 mg/kg piclamilast by 58% and 82%, respectively; and 10, 30 mg/kg 
CDP840 by 36% and 55%, respectively.  Doses of 1, 3 mg/kg rolipram increased pCREB 
in prefrontal cortex by 61% and 70%, respectively, 0.3, 1 mg/kg piclamilast by 59% and 
85% respectively, and 10, 30 mg/kg CDP840 by 32% and 60%, respectively.  None of 
these treatments affected CREB expression (data not shown).   
 
Effects of repeated treatment with rolipram, piclamilast, and CDP840 on 
hippocampal neurogenesis. 
The proliferation and survival of newborn cells in rat hippocampus were measured 
after repeated treatment with rolipram, piclamilast, or CDP840 (Fig.2.3).  Sixteen-day 
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treatment with 1, 3 mg/kg rolipram or 0.3, 1 mg/kg piclamilast increased both cell 
proliferation and survival in the hippocampal samples, but the effects on survival were 
only significant at the higher doses.  Repeated treatment with 30 mg/kg CDP840 
increased cell proliferation but not survival.   
 
Effects of repeated treatment with rolipram, piclamilast, and CDP840 on forced-
swim behavior. 
Repeated treatment with PDE4 inhibitors for sixteen days produced antidepressant-
like effects on the behavior of rats in the forced-swim test in a dose-dependent manner 
(Fig.2.4).  Two hours following the last injection, 1 and 3 mg/kg rolipram, 0.3 and 1 
mg/kg piclamilast, and 10 and 30 mg/kg CDP840reduced the time of immobility.  At the 
doses tested, rolipram and piclamilast tended to produce greater reductions in immobility 
than did CDP840.   
 
Effects of acute treatment with rolipram, piclamilast, and CDP840 on immobility in 
the forced-swim test, cyclic AMP, and pCREB. 
Acute treatment with 3 mg/kg rolipram, 1 mg/kg piclamilast, or 30 mg/kg CDP840 
increased cyclic AMP in prefrontal cortex and hippocampus in a time-dependent manner 
(Table.2.1).  The peak effects of the inhibitors were observed 2 hours post-treatment.  
Similar effects of the PDE4 inhibitors were observed on pCREB in prefrontal cortex and 
hippocampus (Table.2.1), with a peak effect also 2 hours post-treatment.   
Immobility in the forced-swim test was recorded 30 min or 2 hr after administration 
of the PDE4 inhibitors.  Doses of 0.3 mg/kg rolipram, 0.3 mg/kg piclamilast, and 3 mg/kg 
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CDP840 decreased immobility in the forced-swim test at 30 min after acute treatment, 
but not 2 hours post-treatment (Table.2.2).  Acute treatment with higher doses of the 
PDE4 inhibitors did not affect immobility in the forced-swim test at either time point.  
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Discussion 
Repeated treatment with all three PDE4 inhibitors enhanced cyclic AMP signaling in 
hippocampus and prefrontal cortex, as evidenced by increased cAMP and pCREB.  These 
inhibitors also increased hippocampal neurogenesis and produced antidepressant-like 
effects on forced-swim behavior.  However, rolipram and piclamilast, which bind to the 
HARBS with high affinity, were more potent at increasing cAMP/pCREB signaling and 
hippocampal neurogenesis than CDP840, which has lower affinity for the HARBS (Zhao 
et al., 2003b).  Similarly, rolipram and piclamilast were more potent at decreasing the 
time of immobility in the forced-swim test. 
The HARBS and LABRS were first described in a study that showed that [
3
H]-
rolipram binds to recombinant PDE4A with two distinct affinity states with a 500-fold 
difference in Ki values (Jacobitz et al., 1996).  The HARBS is only observed in the 
central nervous system, while the LABRS is present in both the brain and peripheral 
tissues (Zhao et al., 2003b).  While, rolipram exhibits different affinities to the HARBS 
and LARBS, piclamilast exhibits equal high affinity for both (Zhao et al., 2003b), and 
CDP840, by contrast, interacts with relatively low, but similar affinity with both states 
(Zhao et al., 2003b).  The present findings suggest that inhibitor interactions with the 
HARBS are important for mediating neurochemical and behavioral effects of rolipram, 
piclamilast, and CDP840.Repeated treatment with rolipram or piclamilast increased 
cAMP signaling and neurogenesis and produced antidepressant-like behavioral effects at 
doses below those of CDP840 that could effective. 
Previously, it has been found that repeated treatment with the antidepressant drugs 
desipramine and fluoxetine increases the HARBS in brain, measured either by [
3
H]-
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rolipram or [
3
H]-piclamilast binding (Zhao et al., 2003a).  By contrast, such treatment 
does not alter the LARBS in brain.  The effects of fluoxetine and desipramine on the 
HARBS in the brain are prevented when noradrenergic or serotonergic neurons are 
lesioned with 6-hydroxydopamine (6-OHDA) or 5, 7-dihydroxytryptamine (5,7-DHT), 
respectively (Zhao et al., 2003a).  This suggests that the neurochemical pathways 
involved in the mediation of antidepressant activity can influence PDE4 expression and 
activity.  In rats trained to discriminate rolipram from vehicle, only PDE4 inhibitors 
which have a high affinity for the HARBS generalize to rolipram (Zhang et al., 2006).   
Similarly, when the effects of acute treatment with PDE4 inhibitors on forced-swim 
behavior are examined, a potency order of piclamilast > rolipram > CDP840 is observed 
(Zhang et al., 2006); this is consistent with their relative affinities for the HARBS (Zhao 
et al., 2003a). 
Previous studies have shown that hippocampal neurogenesis plays an important role 
in some effects of antidepressants that depend on repeated treatment (Santarelli et al., 
2003). In addition, the time-course of the change in neurogenesis in hippocampus is 
consistent with the delayed onset of antidepressant efficacy (Sahay and Hen, 2007).  
Present studies show that repeated treatment with rolipram and piclamilast also increased 
hippocampal neurogenesis.  Interestingly, repeated treatment with CDP840 at 10 or 30 
mg/kg decreased immobility in forced-swim test, indicating an antidepressant-like effect, 
but did not increase hippocampal proliferation.   Other studies also have shown that some 
antidepressant-like behavioral effects do not depend completely on neurogenesis (Airan 
et al., 2007; David et al., 2007; Wang et al., 2008).  This suggests that neurogenesis 
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might not be the only mechanism underlying PDE4 inhibitor-mediated antidepressant-
like effects on behavior.  
When rats were treated acutely with the PDE4 inhibitors rolipram, piclamilast, or 
CDP840, there was dissociation between neurochemical and behavioral effects.  The 
time- course revealed peak effects at 2 hrs post-acute treatment; by contrast, PDE4 
inhibitors decreased immobility in the forced-swim test 30 min post-treatment, but not at 
2 hrs post-treatment.  In addition, in contrast to the monotonic dose-response curve for 
the effects of repeated treatment, acute treatment with higher doses of the PDE4 
inhibitors no longer decreased immobility.  It is possible that sedative effects of higher 
doses may confound the results in the forced-swim test following acute treatment, but 
that some tolerance may develop with repeated treatment. 
Previous studies have shown that long-term antidepressant treatment increases cyclic 
AMP as well as phosphorylation of CREB in specific brain regions.  The activated cyclic 
AMP/pCREB signaling cascade induces increased expression of brain-derived 
neurotrophic factor (BDNF) in the hippocampus and cerebral cortex (Duman et al., 1997).  
In  addition, chronic administration of either a 5-HT or norepinephrine selective reuptake 
inhibitor, enhances neurogenesis in adult rodent hippocampus via up-regulation of 
cAMP/pCREB signaling (Duman et al., 2001).  Interestingly, cell proliferation is 
decreased in transgenic mice that express a dominant negative mutant of CREB in the 
hippocampus (Nakagawa et al., 2002).  Furthermore, electroconvulsive shock, an 
effective antidepressant therapy, also enhances phosphorylation of CREB in rat 
hippocampus (Jeon et al., 1997).  These studies demonstrate that, like proven 
antidepressants, PDE4 inhibitors produce persistent, enhanced cAMP signaling, altering 
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transcription of neurotrophic factors, increasing hippocampal neurogenesis, and 
contributing to antidepressant-like effects on behavior. 
In a summary, it was found that repeated treatment with PDE4 inhibitors 
increasedcyclic AMP/pCREB signaling and hippocampal neurogenesis and also produced 
antidepressant-like effects on behavior.  Comparison of the neurochemical and behavioral 
effects of rolipram, piclamilast, and CDP840 suggests that interaction with HARBS, in 
contrast to the LARBS, mediates these effects. Improved understanding of molecular 
mechanisms that contribute to the presence of two PDE4 affinity states in the brain may 
suggest targets for antidepressant drug discovery; potential candidate includes scaffolding 
proteins (McCahill et al., 2005; Millar et al., 2005) and unique conserved regions of the 
N-terminal of PDE4 (Burgin et al., 2010).  
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Figure Legends 
 
Fig. 2.1.  Effects of repeated treatment with rolipram, piclamilast, or CDP840 on cyclic 
AMPin rat brain.  Treatment for 16 days with rolipram, piclamilast, or CDP840 increased 
cyclic AMP in hippocampus and prefrontal cortex. Bars represent means ±  SEM, n=3-4 
per group. **P<0.01; *P<0.05 vs. corresponding control. 
 
Fig. 2.2.  Effects of repeated treatment with rolipram, piclamilast, or CDP840 on pCREB 
in rat brain.  Treatment for 16 days with rolipram, piclamilast, or CDP840 increased 
pCREB in hippocampus and prefrontal cortex; none of the treatments affected CREB. 
Bars represent means ± SEM, n=3-4 per group. **P<0.01vs. corresponding control. 
 
Fig. 2.3. Effects of repeated treatment with rolipram, piclamilast, or CDP840 on cell 
proliferation and survival in rat hippocampus. Treatment for 16 days with rolipram or 
piclamilast increased cell proliferation (A) and survival (B).  CDP84030mg/kgtreatment 
increased proliferation (A) but not survival (B).  Bars represent means ± SEM, n=3-4 per 
group.  **P<0.01; *P<0.05 vs. corresponding control. 
 
Fig. 2.4. Effects of repeated treatment with rolipram, piclamilast, or CDP840 on 
immobility of rats in the forced-swim test.  Treatment for 16 days with rolipram, 
piclamilast, or CDP840 decreased immobility time in a dose-dependent manner. Bars 
represent means ± SEM, n=4-5 per group. **P<0.01; *P<0.05 vs. corresponding control. 
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Table 2.1.  Effects of acute treatment with PDE4 inhibitors on cyclic AMP and 
pCREB in hippocampus and prefrontal cortex 
 
 
aValues shown are means  SE expressed as pmol/mg protein cyclic AMP or percentage of control pCREB; n=6 per 
group.   
bNone of the treatments affected CREB.   
**P<0.01; *P<0.05 vs. corresponding control. 
 hours post-treatment 
Control                   0.5                          1                            2                                 3                        4  
Rolipram (3mg/kg) 
cyclic AMP 
pCREBb 
 
cyclic AMP 
pCREB 
Hippocampus 
17.5  1.9a 
100a 
 
24.9  3.5 
101.8  5.0 
 
47.5  4.5* 
131.8  8.2 
 
68.9  5.7** 
182.5  11.0* 
 
47.8  3.0* 
126.3  8.1 
 
23.5  5.0 
116  7.8 
Prefrontal  
18.7  2.7 
100 
cortex 
24.8  3.0 
103  5.9 
 
44.7  5.1* 
123.5  7.5 
 
61.0  7.3** 
160.8 10.5* 
 
40.3  4.2* 
127.5  10.9 
 
25.4  6.0 
116  7.8 
Piclamilast (1mg/kg) 
cyclic AMP 
pCREB 
 
cyclic AMP 
pCREB 
Hippocampus 
21  1.1 
100 
 
38.5  4.7 
102.3  7.4 
 
58.8 6.1** 
117.3  11.6 
 
73  7.9** 
157.3  14.8* 
 
49.5  5.5** 
133.0  8.6 
 
38.5  3.9 
109.8  7.0 
Prefrontal  
18.7  2.7 
100 
cortex 
38.8  4.9 
98.5  9.2 
 
73.3  4.5** 
129.8 9.8 
 
89.3  6.1** 
156  10.0* 
 
52.3  11.5* 
124.3 5.1 
 
36.0  7.1 
101.3 6.8 
CDP840 (30mg/kg) 
cyclic AMP 
pCREB 
 
cyclic AMP 
pCREB 
 
Hippocampus 
22.0  3.9 
100 
 
30.8  3.0 
111.7  2.3 
 
42.7  6.6* 
135.7  16.6 
 
51.5  4.1** 
141.3  9.3* 
 
42.6  5.6* 
125.3  7.2 
 
26.1  2.9 
102.3  3.6 
Prefrontal  
23.8 3.7 
100 
cortex 
29.2  5.6 
111.7  2.4 
 
32.5  2.1 
117.0  8.2 
 
52.2  4.1** 
136.3  12.1* 
 
32.3  4.1 
125.3  7.0 
 
27.8  4.0 
102.3  3.5 
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Table 2.2.  Effects of acute treatment with PDE4 inhibitors on immobility in the 
forced-swim test  
 
 
Immobility (sec) 
   0.5 hr b                                                          2 hr  
  Vehicle 154  10.2a 138  14.2 
Rolipram (mg/kg) 
        0.3 
         1 
         3 
 
84  12.1* 
 
144  7.4 
174  9.2 122  7.0 
201  8.6 127  10.9 
  Piclamilast (mg/kg) 
      0.3 
        1 
       3 
 
58  6.24** 
 
132  5.9 
117  25.5 122  5.8 
129  25.4 123  9.3 
CDP840   (mg/kg) 
      3 
     10 
     30 
 
91  6.5* 
 
141  10.6 
122  19.0 126  12.5 
125  15.0  123  6.1 
 
aValues shown are means  SE for times of immobility of separate groups of rats tested in the forced-swim test; n=6 
per group.   
bRats were treated with PDE4 inhibitors and tested in forced-swim test 0.5 or 2 hr post-treatment. 
**P<0.01; *P<0.05 vs. corresponding control. 
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Figure 2.1 
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Figure2.2 
               
 
 
 
 
 
Vehicle         1        3       0.3      1       10      30  (mg/kg/day)88888Vehicle       1         3         0.3       1           10      30  (mg/kg/day) 
 Rolipram       piclamilast      CDP840                                        Rolipram        piclamilast         CDP840  
 
 
 
 
 
 
 
 
 
pCREB 
 
β actin 
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Figure 2.3 
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Figure 2.4 
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Chapter 3 
Effect of DISC1 mutation on cAMP/pCREB signaling and 
PDE4 isoforms 
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Abstract 
 
Disrupted in schizophrenia 1 (DISC1) is among the most reproducible genetic risk 
factors that have been identified for psychiatric disorders.  Phosphodiesterase-4 (PDE4), 
notably the PDE4B subtype, which interacts strongly with DISC1, is another identified 
risk factor.  The purpose of this study is to investigate how alterations in DISC1 affect 
PDE4 using mutant mice expressing mutated DISC1.  Using a mouse strain carrying an 
endogenous DISC1 construct engineered to model the disease-associated chromosomal 
translocation found in humans, PDE4 expression and activity were examined.  In DISC1 
mutant mice, it was found that PDE4 activity was reduced and cAMP/pCREB singling 
was increased in the hippocampus, prefrontal cortex, and striatum.  Examination of PDE4 
subtypes using SDS-PAGE/immunoblotting showed reduced expression of PDE4B1, 
PDE4B3, and PDE4B4 in these three brain regions.  PDE4D expression was decreased 
only in the hippocampus and PDE4A was not unchanged.  Interestingly, the high affinity 
rolipram binding state, a conformer of PDE4, found only in brain, also was decreased in 
DISC1 mutant mice. These data suggest that DISC1 modulates PDE4 expression and 
function, notably that of the PDE4B subtype, which alters downstream cAMP/CREB 
signaling, which might be involved in DISC1’s role in neuronal function.   
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Introduction 
 
Schizophrenia and depression are common and debilitating mental disorders 
characterized by profound emotional and cognitive disturbances (Millar et al., 2007).  
The onset is determined by multiple factors, and genetic effects are believed to contribute 
to the pathogenesis.  Previous studies have shown that Disrupted-in-Schizophrenia 1 
(DISC1), produced by chromosomal translocation t (1;11)(q42.1; q 14.3) (Millar et al., 
2000b), enhances the risk of developing mental disorders by 50-fold (Blackwood et al., 
2001).  Furthermore, recent studies demonstrate that DISC1 interacts with a number of 
proteins in the central nervous system and is involved in compromised cognitive function 
and behavioral and anatomical changes linked to psychiatric disease (Miyoshi et al., 
2003; Brandon et al., 2004; Hayashi et al., 2005).  These studies indicate that DISC1 is an 
important candidate susceptibility gene for mental illness, including schizophrenia, 
bipolar disorder and major depression (Millar et al., 2000b; Thomson et al., 2005; Chubb 
et al., 2008).  
Phosphodiesterase-4 (PDE4), which is another risk factor for mental disorders, 
contains four genes (PDE4A-D) and acts to catalyze the hydrolysis of cAMP (Houslay 
and Adams, 2003; Millar et al., 2007).  The PDE4B subtype was identified as  risk factor 
in a family diagnosed as schizophrenia and psychotic disorder, who showed an inherited 
t(1;16) chromosomal translocation (Millar et al., 2005; Pickard et al., 2007). Studies 
revealed that mutations in the fruit fly gene that encodes an orthologous PDE4, i.e., the 
dunce gene, showed deficits in synaptic plasticity and learning and memory (Davis et al., 
1995).  In addition, PDE4 inhibitors have antidepressant- and antipsychotic-like effects in 
animal models (Houslay and Adams, 2003; O'Donnell and Zhang, 2004).  Consistent 
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with this, mice with deficient in PDE4D or PDE4B show altered behavior in a number of 
psychopharmacological tests related to anxiolytic, antidepressant, and antipsychotic 
activity (O'Donnell and Zhang, 2004). 
Recent studies show that DISC1 modulates PDE4 activity dynamically by releasing 
PDE4 in response to increased cAMP levels in a protein kinase A- (PKA) dependent 
manner in human neuroblastoma cells (Millar et al., 2005).  Other studies have 
demonstrated that DISC1 and PDE4 isoforms are both present at the same neuron-
specific regions such as synapses (Kirkpatrick et al., 2006; Clapcote et al., 2007) and are 
targeted to particular subcellular compartments (Millar et al., 2005; Lynch et al., 2006; 
Mackie et al., 2007).  Both biochemical and clinical studies indicate that the 
dysregulation of DISC1-PDE4 interaction is likely to contribute to the symptoms of 
severe psychiatric disorders, but the complexities of the DISC1-PDE4 interaction are not 
well understood yet. 
To examine the association between DISC1 and PDE4, we used a mutant DISC1 
mouse strain that carries two termination codons in exons 7 and 8 and a premature 
polyadenylation site in intron 8 (Koike et al., 2006).  In these DISC1 mutant mice, the 
introduced genetic lesion results in the production of a truncated transcript and the 
elimination of a major protein isoform of DISC1 (Kvajo et al., 2008).  In this study, we 
found down-regulated PDE4 activity and enhanced cAMP/pCREB signaling cascade in 
DISC1 mutant mice.  The reduction of PDE4 activity was accompanied by decreased 
expression of PDE4B and high rolipram binding state (HARBS).   
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Materials and Methods 
 
 
Animals  
Mutant DISC1 mice were genetically engineered in the laboratory of Joseph Gogos 
at Columbia University, and contained the same DISC1 mutation backcrossed in 
C57BL/6J, as previously described (Koike et al., 2006). All analyses were performed 
using littermates produced by mating of heterozygous mice. All animal procedures were 
approved by the Columbia University Institutional Animal Care and Use Committee.  
 
 
Measurement of Cyclic AMP  
For cyclic AMP measurement, hippocampus, striatum and prefrontal cortex were 
homogenized in ice-cold 0.1N hydrochloric acid and centrifuged at 13,000 g for 50 min 
at 4ºC.  Cyclic AMP in the supernatant was measured by ELISA (Assay Designs, Ann 
Arbor, MI) (Li et al., 2009). 
 
Western blotting 
For phospho-CREB measurement, hippocampus and prefrontal cortex were 
homogenized in ice-cold lysis buffer (Upstate, Temecula, CA) and then centrifuged at 
10,000g for 30 min at 4C.  Solubilized samples were mixed with equal volumes of 
Laemmli sample buffer and heated to 100C for 2 minutes.  Equal amounts of sample 
protein were loaded onto gels for SDS-PAGE.  Following separation by electrophoresis, 
proteins in the gels were transferred to nitrocellulose membranes, which were incubated 
overnight at 4C with primary antibodies against CREB phosphorylated at serine-133 
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(Upstate Biotechnology, Lake Placid, NY) and then with Alexa Fluor 680-conjugated 
secondary antibody for 30 min at room temperature (Invitrogen, Carlsbad, CA).  An 
Odyssey Infrared Imaging System (LI-COR Bioscience, Lincoln, NE) was used for 
quantifying fluorescence.  Treatment-induced changes in phospho-CREB were assessed 
within individual gels/immunoblots.   
 
Radioligand Binding Assays 
[
3
H]-Rolipram binding was measured as described previously (Zhao et al., 2003a; 
Scharf et al., 2008).  Samples containing 200 g of protein were incubated at 30°C in the 
presence of 250 l of incubation buffer that containing different concentrations of [3H]-
rolipram (2–30 nM).  Nonspecific binding was determined in the presence of 10 nM 
unlabeled Ro 20-1724 [4-3-butoxy-4-methoxybenzyl-2-imidazolidinone] for [
3
H]-
rolipram binding.  Reactions were stopped by addition of 5 ml of ice-cold binding buffer 
after 1 hr and followed by rapid vacuum filtration through glass fiber filters. The filters 
were washed twice, and radioactivity measured by liquid scintillation counting. 
 
PDE Activity Assay 
The PDE enzyme assay was performed as described previously (Zhang et al., 2008).  
Samples were assayed in the presence or absence of 10 uM rolipram.  PDE4 activity i.e. 
rolipram-sensitivity was calculated by subtracting cAMP hydrolysis in the presence of 
rolipram to that in its absence. 
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Real Time-Polymerase Chain Reaction RT-PCR 
Total RNA was isolated from HPC with TRIzol reagent (Invitrogen, Carlsbad, CA) 
according to manufacturer’s instructions, followed by DNase treatment to eliminate 
contaminated genomic DNA.  Conversion of total RNA into cDNA was performed using 
High Capacity cDNA archive kit (Applied Biosystems, Foster City, CA).  Real-time PCR 
was performed on an ABI PRISM 7300 Detection System Applied Biosystems with 
Tagman Universal Mastermix Applied Biosystems. The PDE4B primer was purchased 
from Applied Biosystems. The samples were run in triplicate and amplified for 40 cycles 
at 50°C for 2 min, 90 °C for 10 min, 95 °C for 15 s, extension 60°C for 1 min. Beta-actin 
was used as an endogenous control. The fold difference in expression of target cDNA 
was determined using the comparative threshold method as previously described (Livak 
and Schmittgen, 2001).  
 
Data Analysis and Statistics 
Statistical analysis was performed using one-way analysis of variance followed by 
Dunnett’s test.  Binding data were analyzed by nonlinear regression (O'Donnell et al., 
1984).  Data are expressed as means  SEM.  A p value < 0.05 was considered 
significant. 
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Results 
 
Cyclic AMP and pCREB in the hippocampus, prefrontal cortex and striatum of 
DISC1 mutant mice. 
cAMP levels were significantly increased in the hippocampus, prefrontal cortex and 
striatum of homozygous DISC1 mutant mice compared with wild type mice; no 
significant changes were observed in the same  brain regions of heterozygous DISC1 
mutant mice (Fig.3.1).   Consistently, pCREB demonstrated a trend to increase in the 
three brain regions of homozygous DISC1 mutant mice, but no changes were observed in 
the heterozygous DISC1 mutant mice (Fig.3.2). 
 
PDE4 activity in the hippocampus, prefrontal cortex and striatum of  DISC1 mutant 
mice. 
PDE4 activity was significantly decreased in the hippocampus, prefrontal cortex and 
striatum, by 51%, 38% and 70%, respectively, in the homozygous DISC1 mutant mice 
compared with wild type mice.   In the heterozygous DISC1 mutant mice, PDE4 activity 
was decreased by 29%, 23% and 40%, respectively, in the hippocampus, prefrontal 
cortex and striatum (Fig.3.3). 
 
 
PDE4B levels in the hippocampus, prefrontal cortex and striatum of DISC1 mutant 
mice. 
PDE4B1 was decreased significantly in the hippocampus, prefrontal cortex and 
striatum by 59%, 70% and 50%, respectively, in the homozygous mutant DISC1 mice 
compared to wild type mice.  In heterozygous mice, PDE4B1 was decreased by 11%, 
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32% and 38% (Fig.3.4).  In addition, PDE4B3 was also decreased significantly by 49%, 
52% and 38%, respectively, in the same three brain regions of homozygous mutant 
DISC1 mice, and 11%, 8% and 4% in heterozygous DISC1 mutant mice (Fig.3.6). 
Similarly, PDE4B4 was decreased by 41%, 40% and 30%, respectively, in the 
hippocampus, prefrontal cortex and striatum of homozygous mutant DISC1 mice 
compared to wild type mice.  Reductions were 15%, 19% and 23% in PDE4B4 levels in 
the same brain regions in heterozygous mice (Fig.3.7). No significant changes of 
PDE4B2 were observed in DISC1 mutant mice compared to wild type mice (Fig.3.5).    
Given the marked reductions in protein levels of PDE4B subtypes in DISC1 mutant 
mice, mRNA for PDE4B was measured using real-time RT-PCR.  There were no 
significant changes in mRNA for PDE4B in DISC1 mutant mice indicating that the 
changes observed in PDE4B expression were post-transcriptional (Fig.3.8). 
 
PDE4D levels in the hippocampus, prefrontal cortex and striatum of DISC1 mutant 
mice. 
PDE4D3 was reduced by 40% in the hippocampus, but only 15% and 9% in the 
prefrontal cortex and striatum of homozygous DISC1 mutant mice compared to wild type 
mice.  In heterozygous DISC1 mice, there were 12%, 12% and 7% reductions of 
PDE4D3 in these regions, respectively (Fig.3.9).  Similarly, PDE4D5 also was reduced in 
the hippocampus but not in the prefrontal cortex and striatum of homozygous DISC1 
mutant mice. In heterozygous DISC1 mutant mice, PDE4D5 was not reduced 
significantly (Fig.3.10). 
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PDE4A levels in the hippocampus, prefrontal cortex and striatum of  DISC1 mutant 
mice. 
To reveal whether the mutation of DISC1 affect the PDE4 variant expression, the 
subtypes of PDE4A, including PDE4A1 and PDE4A5 were measured.  There were no 
significant alterations in PDE4A1 in either Hom or Het DSIC1 mutant mice (Fig.3.11). 
Similarly, no changes were found in PDE4A5 in the hippocampus, prefrontal cortex or 
striatum of mutant DISC1 mice, compared with wild type mice (Fig.3.12). 
 
HARBS levels in the hippocampus, prefrontal cortex and striatum of mutant DISC1 
mice. 
In order to study whether the mutation of DISC1 alters the HARBS, the index of the 
HARBS, [
3
H]-rolipram binding, was measured in the DISC1 mutant mice.  [
3
H]-rolipram 
binding were was significantly decreased in the hippocampus, prefrontal cortex and 
striatum of DISC1 mutant mice, including Het and Hom group, compared with wild type 
mice (Fig.3.13). 
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Discussion 
 
DISC1 is involved in multiple neurological signaling cascades, including neuronal 
proliferation and extension (Ishizuka et al., 2006; Mackie et al., 2007; Mao et al., 2009).  
As one of the most important and particularly noteworthy binding partners of DISC1, 
PDE4 is a critical regulator of cAMP.  Our studies demonstrate that PDE4 function and 
downstream cAMP/pCREB signaling cascade were changed by the mutation of DISC1, 
indicating the altered DISC1-PDE4 interaction results in marked changes in cAMP 
signaling, most notably that involving PDE4B.  Ultimately, this could affect neuronal 
progenitor proliferation and neurite extension, promotion of axonal transport and 
neuronal radial migration (Porteous et al., 2003; Ross et al., 2006; Camargo et al., 2007; 
Shinoda et al., 2007; Taya et al., 2007),  and cerebral cortex development (Kamiya et al., 
2005). 
PDE4 activity is regulated by phosphorylation in the catalytic domain by 
extracellular signal-regulated kinase (ERK) and in the UCR1 by protein kinase A (PKA), 
which induces a UCR1-UCR2 interaction (Houslay and Baillie, 2005; Hashimoto et al., 
2006).  Interestingly, recent data have shown that PDE4 activity is dynamically 
modulated by DISC1.  DISC1 binds to the UCR2 domain, and PDE4B dissociates from 
DISC1 in response to increased cAMP (Millar et al., 2005).   This indicates that DISC1 
could exert its effect by modulating PDE4 activity for a variety of biological responses.  
For instance, PDE4 regulates the compartmentalization of cAMP signaling, which is 
linked to the learning, memory and mood (O'Donnell and Zhang, 2004; Arguello and 
Gogos, 2006).   Therefore, mutation of DISC1 could disrupt the normal complex 
interaction, thus interfering with normal learning, memory and cognition, all of which are 
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disturbed in patients with schizophrenia.   Our studies have shown that the mutation of 
DISC1 decreases PDE4 activity, resulting in increased AMP/pCREB signaling, probably 
through the dysregulation of PDE4-DISC1 complex due to the disrupted DISC1 function.  
Similarly, in another animal model of schizophrenia, which involves a missense mutation 
by changing leucine to proline at position 100, PDE4B activity also is reduced (Clapcote 
et al., 2007).  Though decreased PDE4 activity might seem contradictory with the model 
that proposes PDE4B is released from the DISC1-complex in the high activity form, it is 
implied that the reduced association between DISC1-PDE4 induced by mutation might 
not be related to the sequence of events that induces PDE4 dissociation from DISC1 and 
subsequent activation (Millar et al., 2007).  Also, studies of the interaction between 
DISC1-PDE4 are complicated by many factors including studies of differences in cell 
lines, mouse strains, and methods of DISC1 mutation.   Thus, this apparent discrepancy 
needs further investigation to be fully understood. 
Despite these discrepancies, behavioral data offer more evidence of the interaction 
between PDE4 and DISC1.  Mice with a DISC1 mutation demonstrate a schizophrenia-
like phenotype, including hyperactivity and impaired cognition, and these behaviors are 
reversed by the treatment with the PDE4 inhibitor, rolipram or an antipsychotic drug 
(Marx, 2007).  In addition, these mice with depression-like phenotype respond to 
antidepressant treatment in the forced-swim test.  Thus, dysfunction of either DISC1 or 
PDE4 may compromise a variety of signaling cascades and result in distorted neuronal 
development, which underlies the pathogenesis of mental illness.  Additionally, DISC1 
modulation of cAMP via PDE4, could be another target for treating schizophrenia and 
other mental illnesses. 
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PDE4 consists of four subtypes including A, B, C and D.  PDE4A, PDE4B and 
PDE4D are widely expressed throughout the central nervous system, whereas PDE4C is 
expressed only at a minimal level in the brain (O'Donnell and Zhang, 2004).   Molecular 
studies reveal that the association between DISC1 and PDE4 is in a PDE4 isoform-
dependent manner (Murdoch et al., 2007).   Increased cAMP dissociates PDE4C and 
PDE4D from the 100 kDa DISC1, but not the PDE4A or PDE4B isoform; PDE4B does 
dissociate from the 71 kDa DISC1 (Millar et al., 2005; Murdoch et al., 2007).  This is 
explained in part by the number of binding sites between DISC1 and the PDE4 isoforms.  
A peptide array strategy shows that DISC1 has five binding sites for PDE4: two sites for 
every PDE4 isoform; three more specific sites for PDE4B (Murdoch et al., 2007), 
explaining the strong bond between PDE4B and DISC1.  In our study, mutation of 
DISC1 induced a decrease in PDE4B1, PDE4B3, PDE4B5, but not PDE4B2 in the 
prefrontal cortex, hippocampus and striatum, as well as a reduced PDE4D3, PDE4D5 
level in the hippocampus, but no changes of PDE4A isoforms. These data indicate that 
PDE4B is more involved in the interaction with DISC1 and that PDE4A is less 
susceptible to the regulation by altered DISC1.  Consistently, the PDE4B1 isoform was 
found 50% reduced in lymphoblastoid cell line in patients with mental disorders (Millar 
et al., 2005).  PDE4B was also found associated with affective disorders and 
schizophrenia (Pickard et al., 2005).  
PDE4D is highly expressed in the hippocampus and the reduction of PDE4D in this 
region indicates it to have a primary role in the regulation of cAMP signaling; however, 
PDE4D is mainly regulated by phosphorylation (O'Donnell and Zhang, 2004).  
Interestingly, other animal models of schizophrenia, which have mutations from 
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glutamine to leucine at position 31 (31L) or from leucine to proline at position 100 
(100P), decrease binding between DISC1 and PDE4B, particularly for the long isoforms 
PDE4B1 and PDE4B3 (Clapcote et al., 2007).  Clinical studies showed various results 
due to limited sample resources and variations in lifetime drug treatment in patients.  One 
study showed  PDE4B (PDE4B1, PDE4B2, PDE4B3 and PDE4B4) was decreased in the 
cerebella of patients with autism (Braun et al., 2007).   Another study showed PDE4A 
was reduced in cerebella of patients with bipolar disorder, but not in the patients with 
schizophrenia or major depression (Fatemi et al., 2008). 
One complexity in the understanding of PDE4 is the high-affinity and low-affinity 
rolipram binding states (HARBS and LARBS).  It was first described that [
3
H]-rolipram 
bound to brain tissues with high affinity, while to peripheral tissues with low affinity 
(Schneider et al., 1986).  Further studies using recombinant PDE4A revealed that [
3
H]-
rolipram exhibited two distinct affinities with 500-fold differences in Ki (Jacobitz et al., 
1996).  Interestingly, PDE4 is expressed throughout the body, but HARBS is found in the 
CNS but not in peripheral tissues.  Consistent with its location, current studies indicate 
that the CNS effects of PDE4 are mediated mainly by HARBS (O'Donnell and Zhang, 
2004).   In our study, HARBS was decreased in three brain regions of DISC1 mutant 
mice, including the hippocampus, prefrontal cortex and striatum.   Simultaneously, PDE4 
activity was also reduced in the same regions, suggesting decreased HARBS might 
contribute to the reduced PDE4 activity.  Previous studies have shown that repeated 
treatment with desipramine or fluoxetine increases HARBS in cerebral cortex and 
hippocampus (Zhao et al., 2003a), suggesting an alteration in the component of the 
signaling cascade involving PDE4.   
62 
 
In a summary, DISC1 modulates cAMP/pCREB signaling via an interaction with 
PDE4.  DISC1 mutation up-regulates cAMP/pCREB signaling via decreased PDE4 
activity, mainly due to reduced PDE4B and PDE4D variants, while simultaneously 
decreases HARBS.  The DISC1-PDE4 interaction may offer a means to selectively 
reduce the activity of particular PDE4 subtypes, which may offer a unique 
pharmacological profile for the treatment of psychiatric illnesses.   
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Figure Legends 
 
Fig. 3.1. Cyclic AMP levels in the hippocampus, prefrontal cortex and striatum of wild 
type (Wt) and DISC1 mutant mice. Cyclic AMP was increased significantly in the 
hippocampus (A), prefrontal cortex (B) and striatum (C) of homozygous (Hom) DISC1 
mutant mice compared with wild type mice. Values are means ± SEM, n=3-4 per group. 
*P<0.05 vs. corresponding control. 
 
Fig. 3.2. Phospho-CREB levels in the hippocampus, prefrontal cortex and striatum of 
wild type (Wt) and DISC1 mutant mice. Phospho-CREB was significantly increased in 
the prefrontal cortex (B) of homozygous (Hom) DISC1 mutant mice compared with wild 
type mice.  A trend toward an increase in phospho-CREB was observed in the 
hippocampus (A) and striatum (C) in homozygous (Hom) DISC1 mutant mice.  Values 
are means ± SEM, n=3-4 per group. *P<0.05 vs. corresponding control. 
 
Fig. 3.3. PDE4 activity in the hippocampus, prefrontal cortex and striatum of wild type 
(Wt) and DISC1 mutant mice. PDE4 activity was significantly decreased in the 
hippocampus (A), prefrontal cortex (B) and striatum (C) of homozygous (Hom) DISC1 
mutant mice compared to wild type mice.  In addition, PDE4 activity was also decreased 
in the striatum of heterozygous (Het) DISC1 mutant mice. Values are means ± SEM, 
n=3-4 per group. **P<0.01, *P<0.05 vs. corresponding control. 
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Fig. 3.4. PDE4B1 levels in the hippocampus, prefrontal cortex and striatum of wild type 
(Wt) and DISC1 mutant mice. PDE4B1 was decreased in the hippocampus (A), 
prefrontal cortex (B) and striatum (C) of homozygous (Hom) DISC1 mutant mice 
compared with wild type mice.  There was no significant change of PDE4B1 in the 
heterozygous (Het) mice. Values are means ± SEM, n=3-4 per group. *P<0.05 vs. 
corresponding control. 
 
Fig. 3.5. PDE4B2 levels in the hippocampus, prefrontal cortex and striatum of wild type 
(Wt) and DISC1 mutant mice. PDE4B2 showed a trend toward an increase in 
hippocampus (A), prefrontal cortex (B) or striatum (C) of homozygous (Hom) DISC1 
mutant mice compared with wild type mice.  No changes were found in heterozygous 
(Het) mice. Values are means ± SEM, n=3-4 per group.  
 
Fig. 3.6. PDE4B3 levels in the hippocampus, prefrontal cortex and striatum of wild type 
(Wt) and DISC1 mutant mice. PDE4B3 was decreased in the hippocampus (A), 
prefrontal cortex (B) and striatum (C) of homozygous (Hom) DISC1 mutant mice 
compared with wild type mice.  There were no changes in PDE4B3 in the heterozygous 
(Het) mice. Values are means ± SEM, n=3-4 per group. *P<0.05 vs. corresponding 
control. 
 
Fig. 3.7. PDE4B4 levels in the hippocampus, prefrontal cortex and striatum of wild type 
(Wt) and DISC1mutant mice.  PDE4B4 was decreased in the hippocampus (A), 
prefrontal cortex (B), but not in the striatum (C) of homozygous (Hom) DISC1 mutant 
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mice compared with wild type mice. Values are means ± SEM, n=3-4 per group. 
**P<0.01, *P<0.05 vs. corresponding control. 
 
Fig. 3.8. PDE4B mRNA levels in the hippocampus, prefrontal cortex and striatum of 
wild type (Wt) and DISC1mutant mice.  No significant changes were observed in the 
DISC1 mutant mice compared with wild type mice. Values are means ± SEM, n=3-4 per 
group.  
 
Fig. 3.9. PDE4D3 levels in the hippocampus, prefrontal cortex and striatum of wild type 
(Wt) and DISC1 mutant mice.  PDE4D3 was decreased in the hippocampus (A), but not 
prefrontal cortex (B) or striatum (C) of homozygous (Hom) mice compared to wild type 
mice. Values are means ± SEM, n=3-4 per group. **P<0.01 vs. corresponding control. 
 
Fig. 3.10. PDE4D5 levels in the hippocampus, prefrontal cortex and striatum of wild type 
(Wt) and DISC1 mutant mice.  PDE4D5 was changed in the hippocampus (A), but not in 
the prefrontal cortex (B) and striatum (C) of homozygous (Hom) DISC1 mutant mice. 
Values are means ± SEM, n=3-4 per group.  *P<0.05 vs. corresponding control. 
 
Fig. 3.11. PDE4A1 levels in the hippocampus, prefrontal cortex and striatum of wild type 
(Wt) and DISC1 mutant mice. PDE4A1 was not changed in the hippocampus (A), 
prefrontal cortex (B) or striatum (C) of DISC1 mutant mice compared with wild type 
mice. Values are means ± SEM, n=3-4 per group.  
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Fig. 3.12. PDE4A5 levels in the hippocampus, prefrontal cortex and striatum of wild type 
(Wt) and DISC1 mutant mice.  PDE4A5 was not changed in the hippocampus (A), 
prefrontal cortex (B) or striatum (C) of DISC1 mutant mice compared with wild type 
mice. Values are means ± SEM, n=3-4 per group.  
 
Fig. 3.13. HARBS levels in the hippocampus, prefrontal cortex and striatum of wild type 
(Wt) and DISC1 mutant mice. HARBS was decreased in the hippocampus (A), prefrontal 
cortex (B) and striatum (C) in the DISC1 mutant mice compared with wild type mice.  
Values are means ± SEM, n=3-4 per group. **P<0.01, *P<0.05 vs. corresponding 
control. 
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Figure 3.2 
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Figure 3.3 
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Figure 3.4  
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Figure 3.5 
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Figure 3.6 
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Figure 3.7   
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Figure 3.8 
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Figure 3.9 
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Figure 3.10 
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Figure 3.11 
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Figure 3.12 
 
 
 
 
 
 
 
                              
 
 
      
                            
 
PDE4A5 
 
β actin 
Wt000Het00Hom000           0 0Wt000Het0000Hom000    00Wt00000Het000Hom0 
888Hippocampus                             Prefrontal cortex                  Striatum  8 8     8 
 
 
 
 
 
 
 
79 
 
 
Figure 3.13 
 
                          
 
 
 
 
 
 
 
 
 
 
80 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
 
Overall discussion and conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
 
 
PDE4 plays a vital role in maintaining normal function of the central nervous system 
by modulating cAMP levels.  Dysfunction of PDE4 contributes to the changes in 
cognitive function and impaired memory related to the symptoms in psychiatric patients 
(O'Donnell and Zhang, 2004).  Previous studies have indicated that the specific PDE4 
inhibitor rolipram has potent antidepressant effects in both animal models and patients 
with depression.  However, despite the initial promise of PDE4 inhibitors as potent 
antidepressants, its clinical utility has not advanced significantly (O'Donnell and Zhang, 
2004).  This is due to an incomplete understanding of the function of PDE4 subtypes and 
the HARBS and LARBS in PDE4-mediated antidepressant-like effects.  Therefore, it is 
of interest to know how HARBS and LARBS mediate their different pharmacological 
effects in the central nervous system.  In the present study, we examined the differences 
in the effects of three PDE4 inhibitors, which have varying affinities for HARBS and 
LABRS, on cAMP signaling, hippocampal neurogenesis, immobility in forced-swim test, 
and PDE4 subtypes and the HARBS in DISC1 mutant mice. 
To test the antidepressant-like effects in forced-swim test, both acute and repeated 
treatment were used.  Acute treatment at higher doses did not produce any antidepressant-
like effects as evidenced by an increase trend in immobility time likely due to the 
sedative effects. Repeated treatment with PDE4 inhibitors for 16 days decreased 
immobility significantly, compared with control groups.   Compared with CDP840, 
which mainly interacts with the LARBS, lower doses of rolipram and piclamilast exerted 
greater effects in the forced-swim test.  
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Compared with rolipram, piclamilast is about 1000-fold more potent for binding to 
the LARBS and 40-fold more potent for binding to the HARBS (Zhao et al., 2003b).  By 
contrast, CDP840 has a modest affinity for the LARBS and lower affinity to the HARBS.  
Consistent with their functions, HARBS is mainly located in the central nervous system, 
while LARBS in the peripheral tissues and the brain.  In addition, antidepressant 
treatment increased HARBS but not LARBS in the brain (Zhao et al., 2003a).  Taken 
together, the results suggest that the antidepressant-like effects of the PDE4 inhibitors are 
mediated predominantly by the HARBS. 
In order to determine whether HARBS or LARBS is involved in the cAMP signaling 
and hippocampal neurogenesis, the differences in the effects of PDE4 inhibitors on 
cAMP/pCREB and neuronal proliferation were studied. Repeated treatment with three 
PDE4 inhibitors increased cAMP/pCREB signaling, but only rolipram and piclamilast 
enhanced hippocampal proliferation and survival.  By contrast, CDP840, which has 
higher affinity to LARBS, failed to produce similar effects. All three compounds 
demonstrated antidepressant-like effects in forced-swim test, but not all of them enhanced 
hippocampal neurogenesis, indicating enhanced hippocampal neurogenesis is not 
necessary for the PDE4-inhibitor mediated antidepressant-like effects. In addition, 
HARBS seems to be more involved in the hippocampal neurogenesis, when compared 
with LARBS.  These results suggest a close association between the HARBS and 
increased cyclic AMP signaling, neurogenesis, and antidepressant-like effects on 
behavior.  Since side effects, including nausea and sedation, appeared to be mediated by 
the HARBS as well (O'Donnell and Zhang, 2004), simply modifying the affinity of PDE4 
inhibitors for the HARBS might not be enough to develop better medication with fewer 
83 
 
side effects.  However, other alternative approaches, such as targeting the specific 
subtype of PDE4, might produce more desired pharmacological effects. 
To determine the effects of a mutation of DISC1, one of the most important binding 
partners to PDE4, the PDE4 activity and PDE4 splice variants and HARBS were studied 
in the mouse strain carrying truncated DISC1.  The mutation of DISC1 decreased PDE4 
activity in three brain regions, hippocampus, prefrontal cortex and striatum, as well as 
increasing cAMP/pCREB levels.  Similarly, previous studies have reported decreased 
binding of the mutant DISC1 with PDE4B in over-expression systems, coupled with 
decreased activity of PDE4 (Millar et al., 2005).  In another DISC1 mutant line Q31L, 
PDE4 activity was also decreased by 50%.  When these mice were treated with rolipram, 
they seemed resistant (Clapcote et al., 2007).  Rolipram resistance and decreased PDE4 
activity suggest a strong correlation between an elevated cAMP signaling and the 
compromised DISC/PDE4 interaction.  Currently, compelling biological evidence has 
shown that disrupted cAMP signaling mediated by the dysfunction of DISC1/PDE4B 
induces abnormal neurite outgrowth, axonal transport, neuronal migration (Porteous et 
al., 2003; Ross et al., 2006; Camargo et al., 2007; Shinoda et al., 2007; Taya et al., 2007) 
and thus contributes to compromised memory and learning function, and even psychotic 
symptoms in patients with schizophrenia (Pletnikov et al., 2007). 
Though studies show that mutation of DISC1 compromised PDE4 function, it is still 
far from clear which subtype of PDE4 is mainly affected in the central nervous system. 
Molecular studies have demonstrated that DISC1 contains 2 binding sites for PDE4, 3 
more specific binding sites for PDE4B (Millar et al., 2005; Murdoch et al., 2007).  
However, it is not clear whether DISC1 works the same way in the human central 
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nervous system.  In our DISC1 mutant mice, PDE4 splice variant levels, such as 
PDE4B1, B3 and B4, were decreased in three brain regions, and PDE4D were reduced 
only in the hippocampus, while no changes in PDE4A splice variants were observed.  
This suggests that among the PDE4 subtypes, PDE4B is a main binding partner for 
DISC1 and appears to be much more involved in the DISC1/PDE4 interaction.  
Interestingly, among the PDE4B splice variants, PDE4B2 was not decreased 
significantly.  This may due to its structure as a short form of PDE4, which lacks of a 
UCR1 region.  In addition, PDE4D was only altered in the hippocampus, suggesting its 
function is also brain region-dependent.  In addition to studies showing differential 
regulation of PDE4 subtypes after antidepressant treatment, it appears that each PDE4 
splice variants plays a variety of roles in the response to antidepressant treatment and in 
the development of mental disorders.   However, due to the lack of specific PDE4 
subtype inhibitors, the exact function of PDE4 subtypes needs more research to be fully 
understood. 
In order to determine whether DISC1 mutation affects the HARBS, [
3
H]-rolipram 
binding, which is used to label HARBS, was performed.  In both homogenous and 
heterogeneous DISC1 mutant mice, the HARBS was decreased significantly compared 
with wild type mice.  This suggests that the HARBS might be more sensitive to the 
dysfunction of DISC1 or more involved in the DISC1/PDE4 interaction.  As certain 
PDE4 subtypes were also reduced in the same brain regions, it is very possible that most 
of these subtypes of PDE4 exist as HARBS in the CNS.  It is also likely that the mutant 
DISC1 binds to any unknown cellular factors, and thus alters the conformation of PDE4, 
facilitating the transformation from HARBS to LARBS. 
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Currently, there are several animal models of schizophrenia.  In the DISC1 mutant 
mice used in the present study, mutation yielded a truncated DISC1 protein, which was 
rapidly degraded. Compared with wild type mice, these mice demonstrate deficits in 
working memory tasks (Koike et al., 2006; Kvajo et al., 2008), consistent with previous 
studies linking DISC1/PDE4 to cognition function.   In other animal models, which 
express a dominant-negative mutant DISC1, abnormal spatial memory was also observed 
(Pletnikov et al., 2008).  Other animal models with different DISC1 point mutations 
showed schizophrenia-like or depressive-like phenotypes respectively (Clapcote et al., 
2007).  Though these animal models revealed different behavioral abnormalities, it 
appears that these mouse models concur with the human genetic studies.  It suggests that 
there are likely several routes by which DISC1 can perturb brain function leading to 
characteristics of human mental disorders.  It is difficult to expect the phenotypes in the 
animal models of schizophrenia because it is believed to be the culmination of both 
genetic and environmentally elicited changes.  Thus, these mouse models have 
advantages for the studying of both genetic effects and environmental impact for 
psychiatric disorders (Clapcote et al., 2007). 
Collectively, these data characterize the function of HABRS on cAMP/pCREB 
signaling, hippocampal neurogenesis and its corresponding behaviors, as well as the 
interaction between DISC1 and PDE4.  They shed light on the pharmacological effects of 
the HARBS and the complexity of DISC1/PDE4.  However, the role of the HARBS in 
the central nervous system is still relatively unknown, and remains an interesting question 
for the future.  Characterizing the alteration of downstream effectors of DISC1/PDE4 
remains an important area of investigation and could provide us a better understanding of 
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pathogenesis of mental disorders.  It is intriguing that DISC1 interacts with PDE4, 
regulating cAMP signaling and altering PDE4 subtype levels.  This suggests 
compromised cAMP signaling induced by the dysfunction of DISC1/PDE4 is critical for 
the development of mental disorder, and thus it will be very important to determine if the 
DISC1/PDE4 pathway is particularly vulnerable in neuropsychiatric disorders.  
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